Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 159-167
- https://doi.org/10.1016/j.ejca.2017.07.018
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control studyBreast Cancer Research and Treatment, 2016
- Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriersMaturitas, 2010
- Role of Hormone Therapy in the Management of MenopauseObstetrics & Gynecology, 2010
- Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation CarriersJNCI Journal of the National Cancer Institute, 2008
- Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomyFamilial Cancer, 2008
- Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2005
- Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics SystemJournal of Clinical Oncology, 2005
- Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision AnalysisJournal of Clinical Oncology, 2004
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsThe New England Journal of Medicine, 2002
- Incidence of Sexual Dysfunction in Surgically Menopausal WomenMenopause, 1998